Note that the following PDFs listed at the top of this page were handouts shared with the Webinar:
–Phase III Clinical Trial Results at the 48th Union World Conference on Lung Health: Implications for the Field1, PDF
–TB CAB’s Proposed Development Pathway for Regimens to Treat Extensively Drug-Resistant Tuberculosis, PDF
–The Devil We Know: Is the Use of Injectable Agents for the Treatment of MDR-TB Justified? PDF
The Results Are In: Now What? Webinar Video
The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a Webinar held on December 12, 2017. We explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.
- Dr. Francesca Conradie, Wits University
- Dr. Carole Diane Mitnick, Harvard Medical School
- Marcus Low, Spotlight
- Mandy Slutsker, ACTION
- Moderator: Erica Lessem, TAG’s Deputy Executive Director – TB Programs.
Based on the trial results and these discussions, TAG and DR-TB STAT issued the following brief on the shorter regimen: https://www.treatmentactiongroup.org/content/is-shorter-better